Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
“The Quality Director was actually recruited as recently as December 2022,”
I am confused by that Spacman. Richard Francis, SVP, Head of CMC and Quality, was recruited a year earlier when we all thought that Synairgen had a transformative year ahead.
In addition, I am clueless as to any benefit that the CEO’s premature recruitment of executives at around the same time has brought to the company? On that subject, it would be useful to know about the work that is being undertaken by the latest recruits? I know more, via RNS, about their share incentives than their roles.
“Richard Francis joined in September 2021 as Head of CMC, bringing more than 35 years of experience in the development, manufacturing, regulatory approval and commercialization of many biopharmaceutical products including Cablivi®, Orthoclone OKT3®, Remicade®, and ReoPro®.”
Correction 27th april 2023
Mani you are ofcourse allowed your opinion. So Just to add facts. Results announcement
17 april 2023
25 may 2022
12 may 2021
So for now nothing un usual
IMHO
Results are going to be later this year..Why?
They require an update and I am guessing
there is not yet anything positive to report.
He cannot do a working at pace story at this
stage, and must confirm that we have the funds
for upcoming planned trials... I assume funds
are needed and he is trying to secure a deal
that will resolve the funding issues before
releasing results. The pressure is on...!
Elsol the option premium i want to receive for that call option is 7p.
But if i where you and had your believes i would just buy (more) shares dyor
Ok Prof. I will take an option to buy at 20p for 8 months to take your upside as you await your exit price at 20p
Elsol i like sharing.
So willing to let them have them for 20p.
But you can buy them for 20p as well no problem
Pro - that's spineless....surely SNG001 is worth multiples more than that pathetic sum where you would throw in your chips????
The Quality Director was actually recruited as recently as December 2022, which supports the guess that they were still trying to keep the full-service pharma entity idea alive through a pivot to the US at that time (but obviously not for the manufacturing part). Of course we'll never know because the company never explains anything, probably because Marsden has no substantive vision but just a vague dream of the future.
Agree - it's nice to see any mentions and particularly in the specific area that is now so crucial- but the company should be well past all of this now. The P2s are starting within 10 weeks. That's the timescale they promised. The research is done - the assays are made - trialing sites approved and design ready. If this research has somehow made its way into trial design then great but they have to go soon or risk the whole venture. I'd prefer a partner now too - and I've outlined the reasons why before. Even the most optimstic poster would agree that with funds drying up - going broke before the P2s and then P3 (s) deliver is unthinkable
They should have dumped the quality director as soon as it was clear there was no fast route to market: Ie Feb 21st 2022.
20p will give them my shares. I am not greedy ;)
Yes it's favourable but it's very much a sideshow at this point in time. It's what's happening to those things that the company is in control of, front-and-centre, right now, that we need to understand.
Synairgen have just terminated the Quality Director which might suggest that manufacturing capability is no longer their focus, following on from dropping the commercial side. If they are retrenching into R&D and licensing out SNG001 to a third party or through a JV, great. People who talk about resisting a JV and sharing the pie only post-P2, do you really want to risk having 100% of nothing, or would you prefer X% of something? I would rather see a hike in the SP now than trust Marsden & Co. to deliver something bigger, later, on their own.
With any luck, the potential Going Concern audit qualification problem will force a funding solution to be announced pretty shortly.
Mrcosts - "More pin the tail on the donkey."
Isn't that how you decided to invest in sng in the first place?
Where does it mention Synairgen?
Here
“Precision medicine for pandemics: stratification of COVID-19”
And Here
Together with Scientists from Medicine and Biological Sciences and University spin out company, Synairgen, TopMD will lead molecular phenotyping in a €14m EU-funded international consortium for COVID-19 advanced diagnostics.
TopMD co-founders, James Schofield, Lecturer in Systems Biomedicine and Paul Skipp, Associate Professor in Proteomics will work with a number of other University of Southampton researchers and academics in leading the DRAGON project.
And Here
“A significant proportion of medical research seeks to better understand
complex, heterogeneous patient and population groups, and to divide them
into subclasses defined by markers.
Stratified, precision, P4 or personalised medicine has the ultimate goal to
ensure that the right patient receives the right therapy at the right time“
https://synairgen.ams3.digitaloceanspaces.com/230629-Synairgen-AGM-2023_FINAL.pdf
Synairgen have always been in the foreground of this kind of collaborative process.
So its agreed the article doesn't mention SNG001 or Synairgen directly?
More pin the tail on the donkey.
Surely you know how to find and follow references in a medical paper Mr Costs
Brand - please copy and paste part(s) of the article which mentions SNG001 or Synairgen directly.
"No mention of SNG001 or Synairgen."
Tell me you haven't read it without telling me you haven't read it :-)
It seems one of the many interests are co founder has is
Precision medicine for pandemics!
I wonder who else in BP and world government organisations might have similar interests?
Not really a great find is it. No mention of SNG001 or Synairgen.
Our co founder is mentioned who also happens to have many interests outside of Synairgen. So What?
All this flirting could be sorted with an update from the company themselves.
Great Find
Synairgen’s co founder in the list
Precision Medicine, Stratification, SNG, TopMD, Leading Global Universities..
Looks to be a lot of dots connecting with this one.
https://www.medrxiv.org/content/10.1101/2024.04.15.24305820v2
You could not be more correct in your post T_P. I agree whole heartily with you.
I just want an update for all of us!I’ve really had enough of no comms from this CEO and the company in general.
Wishing you all a good weekend ahead and the small hope of any info from them today, but it would be nice!
GLA!
It doesn’t really matter what any of this board’s contributors are doing with Synairgen stock. There is nothing illegal in day trading or short-term selling. It would be an improvement of this forum if no one mentioned this again.
MrCosts must have climbed out of Aether’s green bin at least fifty times by now, followed closely by Professional. Everyone in my green bin doesn’t get mentioned again, as I don’t read their posts! (Neither of the former two contributors are in it, by the way.)
The only issue for me is that elusive Synairgen RNS, announcing that the company is back on track! I have waited for nearly twenty six months for some news of a trial and it is long overdue as far as I am concerned! What I don’t want is more vague BS from the CEO and his acolytes at the next AGM!
GLALTIs.
Mani no.
I am all for balance. I have enough negatives about this company and management . Yours is just false. Imho ofcourse.
And yes i think risk/reward for the stock is positive at this sp level
Wether you buy sell or short i really do not care. Go for it.